Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US manufacturers face high costs under MRA (mutual recognition agreement) with Europe

This article was originally published in Clinica

Executive Summary

US manufacturers may have to pay over twice as much as their European counterparts to have their devices assessed under the mutual recognition agreement (MRA) between the EU and the US. The FDA's Devices and Diagnostics Letter suggests that the FDA is considering reimbursing US companies for the additional costs, otherwise there may be little incentive for them to use the testing laboratories designated under the MRA as conformity assessment bodies (CABs). Under the MRA, European companies can use a CAB in Europe trained to test to US requirements for products intended for the US market, while US firms can use CABs in the US trained to test to EU requirements.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075413

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel